Skip to main content
. 2024 Mar 5;20(3):e1011881. doi: 10.1371/journal.pcbi.1011881

Fig 4. The median number of germline liabilities in therapeutics.

Fig 4

We counted the number of detected liabilities in each therapeutic sequence. These were further stratified by detected germlines. We show the number of liabilities for A) Heavy chains B) Light lambda chains and C) Light Kappa chains.